share_log
Reuters ·  08/19 09:00

Tuhura Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for Vista-101 Clinical Trial Evaluating Kva12123 in Patients With Advanced Solid Tumor Cancer

Tuhura Biosciences和kintara therapeutics宣佈Kineta公司重新開放招募參與高級實體瘤癌患者評估kva12123的Vista-101臨床試驗

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論